2024/10/18 22:26:42 | |
---|---|
Price | |
9.82 EUR | |
Difference | 17.75% (1.48) |
ISIN | IT0004147952 |
Symbol | NWRN |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 184 EUR |
Benchmark | FTSE MIB INDEX |
Bid (Bid size) | 9.65 EUR (350) |
Ask (Ask size) | 9.99 EUR (100) |
Open | 8.47 EUR |
High | 10.18 EUR |
Low | 8.36 EUR |
Close (prev. day) | 8.34 EUR |
VWAP | 9.49753 EUR |
Volume (pcs) | 13,939 |
Trading volume | 132,386.13 |
Number of trades | 62 |
Last size | 100 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings |
2024/10/18 22:26:42 | |
---|---|
Price | |
9.82 EUR | |
Difference | 17.75% (1.48) |
ISIN | IT0004147952 |
Symbol | NWRN |
Exchange | Tradegate |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 184 EUR |
Benchmark | FTSE MIB INDEX |
Bid (Bid size) | 9.65 EUR (350) |
Ask (Ask size) | 9.99 EUR (100) |
Open | 8.47 EUR |
High | 10.18 EUR |
Low | 8.36 EUR |
Close (prev. day) | 8.34 EUR |
VWAP | 9.49753 EUR |
Volume (pcs) | 13,939 |
Trading volume | 132,386.13 |
Number of trades | 62 |
Last size | 100 |
6m | 1Y | 3Y | |
Perf (%) | +40.00% | +83.18% | +422.95% |
Perf (abs.) | +2.80 | +4.45 | +7.93 |
Beta | 1.25 | 1.38 | 0.43 |
Volatility | 65.96 | 80.80 | 83.33 |
Ø price 5 days | Ø volume 5 days (pcs.) | 8.75 EUR (6,265) |
Ø price 30 days | Ø volume 30 days (pcs.) | 8.41 EUR (6,473) |
Ø price 100 days | Ø volume 100 days (pcs.) | 8.78 EUR (6,317) |
Ø price 250 days | Ø volume 250 days (pcs.) | 8.06 EUR (10,087) |
YTD High | date | 13.30 EUR (2024/04/30) |
YTD Low | date | 5.00 EUR (2024/01/03) |
52 Weeks High | date | 13.30 EUR (2024/04/30) |
52 Weeks Low | date | 4.26 EUR (2023/11/23) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/10/18 | 17:35 | 9.32 EUR | 0.12 | 34 |
Tradegate | 2024/10/18 | 22:26 | 9.82 EUR | 0.13 | 62 |
SIX Swiss Exchange | 2024/10/18 | 17:30 | 8.98 CHF | 1.54 | 437 |
Munich | 2024/10/18 | 17:27 | 9.44 EUR | 0.00 | 3 |
London Stock Exchange | 2024/04/29 | 09:33 | 7.1083 CHF | 0.01 | 1 |
Frankfurt | 2024/10/18 | 18:05 | 9.90 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/09/09 | 21:02 | 9.36 USD | 0.01 | 2 |
Duesseldorf | 2024/10/18 | 19:31 | 9.77 EUR | 0.00 | 4 |
Berlin | 2024/10/18 | 19:33 | 9.95 EUR | 0.00 | 16 |
NEWRON PHARMACEUTICALS SPA |
- - |
via Antonio Meucci 3 - 20091 Bresso |
Telefon: +39-02-610-3461 |
Fax: +39-02-610-34654 |
E-mail: info@newron.com |
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy. |
Stefan Weber | Chairman of Managing Board |
Dennis Dionne | Member of Executive Committee |
Filippo Moriggia | Member of Executive Committee |
Laura Faravelli | Member of Executive Committee |
Ravi Anand | Member of Executive Committee |
Roberto Galli | Member of Executive Committee |
Ulrich Köstlin | Chairman of Supervisory Board |
Luca Benatti | Member of Supervisory Board |
Patrick Langlois | Member of Supervisory Board |
Gillian Dines | Member of Supervisory Board |
Margarita Chavez | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer